ClinicalTrials.gg

Program

SLN12140

A development code.

Its studies are mostly in Glomerulonephritis, IGA · Hemoglobinuria, Paroxysmal, led by Linno Pharmaceuticals.

Furthest: phase 2, since Jan 22, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Linno Pharmaceuticals33 open or runningphase 2since Jan 22, 2026Apr 10, 2025Dec 2027phase 2 · NCT07553494

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 10, 2025First study: phase 1 study in Healthy VolunteerFirst studyNCT06945445 · 56 planned · China
  2. Jan 22, 2026Phase 2 study in Hemoglobinuria, ParoxysmalPhase 2 reachedNCT07387302 · 10 planned
  3. Apr 14, 2026Phase 2 study in Glomerulonephritis, IGANCT07553494 · 48 planned · China

Ahead

  1. Dec 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT07553494

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07553494Glomerulonephritis, IGA · China2Not yet recruitingDec 202748
NCT07387302Hemoglobinuria, Paroxysmal2Not yet recruitingJul 31, 202610
NCT06945445Healthy Volunteer · China1Not yet recruitingMay 202656

How it is read

Names in the registry

  • “SLN12140”, 3 entries

Codes read as this program: SLN12140.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.